The global anti-obesity drugs (AOM) market is projected to expand strongly 13-15 percent The CAGR to 2034 is primarily driven by the rapid adoption of GLP-1-based therapies. This surge is not only accelerating demand for effective weight-loss treatments, but is also catalyzing innovation in oral GLP-1 delivery, as companies seek more patient-friendly alternatives to injectables.
Lexaria Bioscience (NASDAQ:LESX), with a market capitalization of approximately US$22.37 million, is focused on addressing key limitations of current treatments by improving tolerability and convenience without compromising efficacy. Its approach targets one of the field’s most pressing needs: enhancing patient adherence and the overall treatment experience.
At the core of Lexaria’s strategy is its proprietary DeHydraTech™ platform, designed to optimize the delivery of orally administered medications. By improving bioavailability and reducing adverse side effects, the technology aims to enhance both therapeutic performance and patient compliance, while preparing the company for potential licensing partnerships with major pharmaceutical players.
In advanced development since 2015, DihydraTech is supported by extensive Pharmacokinetic research. The platform is protected by a growing intellectual property portfolio, including at least 65 granted patents and additional applications spanning multiple indications including diabetes, hypertension, epilepsy, antiviral therapy, central nervous system disorders and phosphodiesterase type 5 inhibitors.
Company Highlights
- Proprietary DeHydraTech™ platform Improves oral bioavailability and tolerability of active pharmaceutical ingredients (APIs), including GLP-1 drugs
- 65 patents granted globally In many areas, with more waiting
- Positive human and preclinical study results GLP-1 drug formulations exhibit better absorption and fewer side effects
- Positioned to take advantage of the rapid increase in oral GLP-1 therapyFollowing recent FDA approvals, which include Novo Nordisk’s Vegovy® pill and Eli Lilly Foundaio™
